Do analysts recommend RNXT or ORMP?

RenovoRx presently has a consensus target price of $8.50, indicating a potential upside of 789.87%. Given RenovoRx's stronger consensus rating and higher probable upside, analysts clearly believe RenovoRx is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RenovoRx 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to RNXT or ORMP?

In the previous week, Oramed Pharmaceuticals had 1 more articles in the media than RenovoRx. MarketBeat recorded 3 mentions for Oramed Pharmaceuticals and 2 mentions for RenovoRx. Oramed Pharmaceuticals' average media sentiment score of 0.98 beat RenovoRx's score of 0.93 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RenovoRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oramed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RNXT or CRBU more profitable?

RenovoRx has a net margin of -823.98% compared to Caribou Biosciences' net margin of -1,189.14%. Caribou Biosciences' return on equity of -84.17% beat RenovoRx's return on equity. Company Net Margins Return on Equity Return on Assets RenovoRx -823.98% -135.03% -101.92% Caribou Biosciences -1,189.14% -84.17% -60.51%

Does the media favor RNXT or CRBU?

In the previous week, RenovoRx and RenovoRx both had 2 articles in the media. RenovoRx's average media sentiment score of 0.93 equaled Caribou Biosciences'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RenovoRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Caribou Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RNXT or MOLN?

In the previous week, RenovoRx and RenovoRx both had 2 articles in the media. RenovoRx's average media sentiment score of 0.93 equaled Molecular Partners'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RenovoRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RNXT or CRBP?

In the previous week, Corbus Pharmaceuticals had 1 more articles in the media than RenovoRx. MarketBeat recorded 3 mentions for Corbus Pharmaceuticals and 2 mentions for RenovoRx. RenovoRx's average media sentiment score of 0.93 beat Corbus Pharmaceuticals' score of 0.62 indicating that RenovoRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RenovoRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corbus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

RenovoRx (RNXT) Competitors

$0.96 -0.02 (-2.53%)

Closing price 04:00 PM Eastern

Extended Trading

$0.95 -0.01 (-0.75%)

As of 04:10 PM Eastern

Compare

RNXT vs. ORMP, MIST, CRBU, MOLN, and CRBP

Should you buy RenovoRx stock or one of its competitors? MarketBeat compares RenovoRx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with RenovoRx include Oramed Pharmaceuticals (ORMP), Milestone Pharmaceuticals (MIST), Caribou Biosciences (CRBU), Molecular Partners (MOLN), and Corbus Pharmaceuticals (CRBP). These companies are all part of the "pharmaceutical products" industry.

How does RenovoRx compare to Oramed Pharmaceuticals?

RenovoRx (NASDAQ:RNXT) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Oramed Pharmaceuticals has higher revenue and earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	38.46	-$11.17M	-$0.33	N/A
Oramed Pharmaceuticals	$2M	94.34	$64.05M	$2.59	1.78

3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 9.4% of RenovoRx shares are owned by insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

RenovoRx has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

In the previous week, Oramed Pharmaceuticals had 1 more articles in the media than RenovoRx. MarketBeat recorded 3 mentions for Oramed Pharmaceuticals and 2 mentions for RenovoRx. Oramed Pharmaceuticals' average media sentiment score of 0.98 beat RenovoRx's score of 0.93 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oramed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oramed Pharmaceuticals has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. Oramed Pharmaceuticals' return on equity of -5.37% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-823.98%	-135.03%	-101.92%
Oramed Pharmaceuticals	N/A	-5.37%	-4.83%

RenovoRx presently has a consensus target price of $8.50, indicating a potential upside of 789.87%. Given RenovoRx's stronger consensus rating and higher probable upside, analysts clearly believe RenovoRx is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Oramed Pharmaceuticals beats RenovoRx on 13 of the 17 factors compared between the two stocks.

How does RenovoRx compare to Milestone Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

Milestone Pharmaceuticals has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, RenovoRx has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market.

RenovoRx has lower revenue, but higher earnings than Milestone Pharmaceuticals. RenovoRx is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	106.03	-$63.06M	-$0.68	N/A
RenovoRx	$1.12M	38.46	-$11.17M	-$0.33	N/A

In the previous week, RenovoRx had 1 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 2 mentions for RenovoRx and 1 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 1.89 beat RenovoRx's score of 0.93 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Milestone Pharmaceuticals	Very Positive
RenovoRx	Positive

Milestone Pharmaceuticals presently has a consensus target price of $7.25, indicating a potential upside of 449.24%. RenovoRx has a consensus target price of $8.50, indicating a potential upside of 789.87%. Given RenovoRx's stronger consensus rating and higher probable upside, analysts clearly believe RenovoRx is more favorable than Milestone Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 9.4% of RenovoRx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Milestone Pharmaceuticals has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. RenovoRx's return on equity of -135.03% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%
RenovoRx	-823.98%	-135.03%	-101.92%

Summary

Milestone Pharmaceuticals and RenovoRx tied by winning 8 of the 16 factors compared between the two stocks.

How does RenovoRx compare to Caribou Biosciences?

RenovoRx (NASDAQ:RNXT) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

In the previous week, RenovoRx and RenovoRx both had 2 articles in the media. RenovoRx's average media sentiment score of 0.93 equaled Caribou Biosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caribou Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RenovoRx presently has a consensus target price of $8.50, indicating a potential upside of 789.87%. Caribou Biosciences has a consensus target price of $8.67, indicating a potential upside of 392.42%. Given RenovoRx's higher probable upside, analysts clearly believe RenovoRx is more favorable than Caribou Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

RenovoRx has a net margin of -823.98% compared to Caribou Biosciences' net margin of -1,189.14%. Caribou Biosciences' return on equity of -84.17% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-823.98%	-135.03%	-101.92%
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%

RenovoRx has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.37, meaning that its share price is 137% more volatile than the broader market.

3.1% of RenovoRx shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 9.4% of RenovoRx shares are held by insiders. Comparatively, 8.5% of Caribou Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

RenovoRx has higher earnings, but lower revenue than Caribou Biosciences. RenovoRx is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	38.46	-$11.17M	-$0.33	N/A
Caribou Biosciences	$11.16M	15.64	-$148.12M	-$1.42	N/A

Summary

RenovoRx and Caribou Biosciences tied by winning 6 of the 12 factors compared between the two stocks.

How does RenovoRx compare to Molecular Partners?

RenovoRx (NASDAQ:RNXT) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

RenovoRx has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Molecular Partners has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. Molecular Partners' return on equity of -66.62% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-823.98%	-135.03%	-101.92%
Molecular Partners	N/A	-66.62%	-54.85%

3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 9.4% of RenovoRx shares are owned by insiders. Comparatively, 5.9% of Molecular Partners shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

RenovoRx presently has a consensus target price of $8.50, indicating a potential upside of 789.87%. Molecular Partners has a consensus target price of $8.38, indicating a potential upside of 113.10%. Given RenovoRx's stronger consensus rating and higher probable upside, research analysts plainly believe RenovoRx is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

RenovoRx has higher earnings, but lower revenue than Molecular Partners. RenovoRx is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	38.46	-$11.17M	-$0.33	N/A
Molecular Partners	$5.65M	28.09	-$74.41M	-$1.94	N/A

In the previous week, RenovoRx and RenovoRx both had 2 articles in the media. RenovoRx's average media sentiment score of 0.93 equaled Molecular Partners'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

RenovoRx and Molecular Partners tied by winning 7 of the 14 factors compared between the two stocks.

How does RenovoRx compare to Corbus Pharmaceuticals?

RenovoRx (NASDAQ:RNXT) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

RenovoRx has higher revenue and earnings than Corbus Pharmaceuticals. RenovoRx is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.12M	38.46	-$11.17M	-$0.33	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A

RenovoRx has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.55, suggesting that its share price is 155% more volatile than the broader market.

3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 9.4% of RenovoRx shares are owned by company insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Corbus Pharmaceuticals has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. Corbus Pharmaceuticals' return on equity of -70.89% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-823.98%	-135.03%	-101.92%
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%

RenovoRx currently has a consensus price target of $8.50, indicating a potential upside of 789.87%. Corbus Pharmaceuticals has a consensus price target of $40.67, indicating a potential upside of 348.36%. Given RenovoRx's higher possible upside, analysts clearly believe RenovoRx is more favorable than Corbus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Corbus Pharmaceuticals had 1 more articles in the media than RenovoRx. MarketBeat recorded 3 mentions for Corbus Pharmaceuticals and 2 mentions for RenovoRx. RenovoRx's average media sentiment score of 0.93 beat Corbus Pharmaceuticals' score of 0.62 indicating that RenovoRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corbus Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Corbus Pharmaceuticals beats RenovoRx on 8 of the 14 factors compared between the two stocks.

Get RenovoRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNXT vs. The Competition

Export

Metric	RenovoRx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$44.20M	$3.67B	$6.81B	$12.59B
Dividend Yield	N/A	2.21%	2.67%	6.75%
P/E Ratio	-2.89	11.81	23.37	23.12
Price / Sales	38.46	324.37	533.70	99.94
Price / Cash	N/A	141.54	47.99	59.26
Price / Book	6.37	8.71	10.96	6.62
Net Income	-$11.17M	$23.87M	$3.57B	$336.83M
7 Day Performance	0.23%	3.31%	2.58%	2.52%
1 Month Performance	3.75%	3.33%	1.67%	0.44%
1 Year Performance	-24.79%	66.60%	35.96%	29.40%

RenovoRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNXT RenovoRx	4.3498 of 5 stars	$0.96 -2.5%	$8.50 +789.9%	-25.5%	$44.20M	$1.12M	N/A	6	News Coverage Analyst Downgrade Gap Down
ORMP Oramed Pharmaceuticals	2.9633 of 5 stars	$4.17 +4.0%	N/A	+113.8%	$164.11M	$2M	1.61	10
MIST Milestone Pharmaceuticals	2.4345 of 5 stars	$1.30 -0.8%	$7.25 +457.7%	-30.9%	$163.09M	$1.55M	N/A	30
CRBU Caribou Biosciences	2.1996 of 5 stars	$1.66 +1.2%	$8.67 +422.1%	+39.7%	$162.66M	$11.16M	N/A	100
MOLN Molecular Partners	2.8435 of 5 stars	$3.84 -2.8%	$8.38 +118.1%	+2.1%	$159.48M	$5.65M	N/A	180	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNXT) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RenovoRx (RNXT) Competitors

RNXT vs. ORMP, MIST, CRBU, MOLN, and CRBP

How does RenovoRx compare to Oramed Pharmaceuticals?

Summary

How does RenovoRx compare to Milestone Pharmaceuticals?

Summary

How does RenovoRx compare to Caribou Biosciences?

Summary

How does RenovoRx compare to Molecular Partners?

Summary

How does RenovoRx compare to Corbus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNXT vs. The Competition

RenovoRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RenovoRx (RNXT) Competitors

RNXT vs. ORMP, MIST, CRBU, MOLN, and CRBP

How does RenovoRx compare to Oramed Pharmaceuticals?

Which has better earnings and valuation, RNXT or ORMP?

Do insiders and institutionals believe in RNXT or ORMP?

Which has more volatility and risk, RNXT or ORMP?

Does the media refer more to RNXT or ORMP?

Is RNXT or ORMP more profitable?

Do analysts recommend RNXT or ORMP?

Summary

How does RenovoRx compare to Milestone Pharmaceuticals?

Which has more risk & volatility, MIST or RNXT?

Which has higher valuation and earnings, MIST or RNXT?

Does the media favor MIST or RNXT?

Do analysts rate MIST or RNXT?

Do insiders & institutionals have more ownership in MIST or RNXT?

Is MIST or RNXT more profitable?

Summary

How does RenovoRx compare to Caribou Biosciences?

Does the media favor RNXT or CRBU?

Do analysts recommend RNXT or CRBU?

Is RNXT or CRBU more profitable?

Which has more risk and volatility, RNXT or CRBU?

Do institutionals & insiders have more ownership in RNXT or CRBU?

Which has stronger valuation and earnings, RNXT or CRBU?

Summary

How does RenovoRx compare to Molecular Partners?

Which has more risk and volatility, RNXT or MOLN?

Is RNXT or MOLN more profitable?

Do institutionals and insiders believe in RNXT or MOLN?

Do analysts prefer RNXT or MOLN?

Which has better valuation & earnings, RNXT or MOLN?

Does the media favor RNXT or MOLN?

Summary

How does RenovoRx compare to Corbus Pharmaceuticals?

Which has stronger valuation & earnings, RNXT or CRBP?

Which has more volatility & risk, RNXT or CRBP?

Do insiders and institutionals believe in RNXT or CRBP?

Is RNXT or CRBP more profitable?

Do analysts rate RNXT or CRBP?

Does the media refer more to RNXT or CRBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNXT vs. The Competition

RenovoRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools